University of GenevaFinancingFoRx raises US$50m in Series A to advance PARG inhibitorSwiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026. more ➔
MRM Health NVAntiinflammationBelgian microbiome player MRM Health initiates R&D partnership in cancer immunotherapyFollowing a €55m (US$64m) Series B financing in September, Ghent-based MRM Health today announced a strategic collaboration with the research group of Professor Emile Voest, Senior Group Leader at … more ➔
EC- press serviceEUBiopharmaceutical sector welcomes EU Biotech ActThe European Commission has unveiled the first part of its draft for a Biotech Act, focusing on health and medical biotechnology. The proposal has won strong support from industry stakeholders, who … more ➔
John Kiel - wikipediaM&ASobi strengthens gout pipeline with Arthrosi acquisitionSobi AB has completed the US$1.5bn acquisition of Chinese Arthrosi Therapeutics Ltd. Its lead candidate, pozdeutinurad, a URAT1 inhibitor for gout, is in pivotal global Phase-III trials, with China licensing … more ➔
Sanofimultiple sclerosisSanofi facing tolebrutinib setback in MSSanofi’s tolebrutinib fails Phase III in PPMS, while FDA postpones decision on targeted therapy approval for nrSPMS. more ➔
FIDA Biosystems ApSFinancingEifo and Fsg back Fida Biosystems with €5m investmentFida Biosystems ApS has added €5m from EIFO and FSG to an ongoing Series A financing to scale its Flow-Induced Dispersion Analysis platform, advancing in-solution biophysical analysis for drug d … more ➔
VFAClinical studiesGerman pharma association publishes clinical trial rankingThe German pharmaceutical association vfa has updated its ranking of the best locations for industry-sponsored clinical trials. In Europe, Spain retained its top position in 2024, followed by Australia, … more ➔
Van Overeem Nuclear BVCancer radiopharmaceuticalsRadioMedix expands thorium-228 supply for 212PbRadiopharmaceuticals specialist RadioMedix Inc has secured five-year Thorium-228 supply from Van Overeem, strengthening 212Pb production and Targeted Alpha Therapy pipeline development. more ➔
ObesityZealand pays Chinese OTR US$30m upfront to expand obesity pipelineDanish Zealand Pharma A/S partners with Chinese start-up OTR Therapeutics Co. Ltd to expand oral obesity pipeline in US$30m upfront deal. more ➔
Momoneymoproblemz - wikimediaObesityLilly‘s retatrutide delivers record weight lossLilly’s triple weight loss combination therapy retatrutide has shown 28.7% weight loss in Phase 3, but higher discontinuations vs. tirzepatide and semaglutide. more ➔
University of Geneva
MRM Health NV
EC- press service
John Kiel - wikipedia
Sanofi
FIDA Biosystems ApS
VFA
Van Overeem Nuclear BV
Momoneymoproblemz - wikimedia